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compare guideline-adherent and routine clinical practice. Value of information analy-
sis will be employed to identify areas for future research. We are applying this trans-
lational approach to various current and developing examples of PM in cancer: 1) 
trastuzumab for human-epidermal growth factor receptor-2 positive BC; 2) gene-
expression proﬁling to identify patients who will beneﬁt most from adjuvant treatment 
in BC; 3) cytochrome P450 2D6 testing to select patients for adjuvant tamoxifen 
therapy in BC; and 4) testing for Lynch Syndrome in CRC patients and their family 
members to inform treatment and preventative interventions. This research will 
develop evidence-based information for patients, providers, industry, researchers and 
policymakers to objectively assess how PM can be beneﬁcial and efﬁcient in improving 
cancer outcomes.
PODIUM SESSION III: RESEARCH ON THE USE OF UTILITY 
MEASUREMENT
UT1
ASSOCIATION BETWEEN UTILITY AND TREATMENT AMONG 
PROSTATE CANCER PATIENTS
Jayadevappa R, Chhatre S, Malkowicz B
University of Pennsylvania, Philadelphia, PA, USA
OBJECTIVES: To analyze the association between utility, treatment and generic and 
prostate-speciﬁc health related quality of life (HRQoL) among prostate cancer 
patients. METHODS: In this longitudinal cohort study we recruited 201 (≥45 yrs) 
newly diagnosed prostate cancer patients from urology clinics of an urban academic 
hospital. Participants completed Quality of Wellbeing (QWB-SA), generic (SF-36) and 
prostate-speciﬁc (UCLA-PCI) HRQoL surveys prior to treatment and up to 24 months 
post-treatment. Clinical and demographic data were obtained via medical chart review 
and utility scores were computed using QWB-SA. To analyze the relationship between 
treatment and utility we used linear mixed effects models, after adjusting for covari-
ates. Similar models were used to examine association between generic and prostate-
speciﬁc HRQoL and utility. RESULTS: Mean baseline utility was comparable between 
radical prostatectomy (RP) and external beam radiation therapy (EBRT) groups (0.73 
vs. 0.69, p = 0.1750). Mixed effects models indicated that RP was associated with 
higher utility at 24 month (OR = 1.12, p = 0.027), after controlling for covariates. 
RP was associated with improved functioning for role physical, role emotional, vital-
ity, mental health and bodily pain and impaired urinary function. Higher scores on 
generic health subscales were indicative of higher utility. Also, for prostate-speciﬁc 
HRQoL, higher scores on bowl function, sexual function, urinary bother and bowel 
bother were associated higher utility. CONCLUSIONS: Treatment appears to have 
signiﬁcant association with post-treatment utility. Thus, utility assessment provides an 
important quantitative tool to support patient and physician clinical treatment deci-
sion making process of prostate cancer care.
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COMPARISON OF HEALTH STATE UTILITY ESTIMATES IN  
COST-EFFECTIVENESS ANALYSIS
Slejko JF1, Ghushchyan VH1, Sullivan PW2
1University of Colorado Denver, Aurora, CO, USA, 2Regis University School of Pharmacy, 
Denver, CO, USA
OBJECTIVES: This study examined the effect of different utility instruments and 
tariffs on chronic condition utility scores and incremental cost-effectiveness ratios 
(ICERs). METHODS: Postponement of diabetes was modeled in a high-risk popula-
tion receiving a hypothetical intervention, as compared to a similar control group. 
Utility estimates for the general population, diabetes, hypertension, stroke, myocardial 
infarction (MI) and congestive heart failure (CHF) were taken from catalogues devel-
oped by Sullivan et al. for United States and United Kingdom EuroQOL-5D tariffs 
(EQ-5DUS and EQ-5DUK) and SF-6D, using the Medical Expenditure Panel Survey. 
Quality-adjusted life-years (QALYs) were modeled for 20 years using a 3% discount 
rate. The discounted cost of the intervention was assumed to be $150,000. RESULTS: 
The initial health state utility was lowest using the SF-6D(.709), and highest using 
EQ-5DUS(.800). The highest estimates for diabetes(.708), hypertension(.761) and 
MI(.575) were found using EQ-5DUS, but the highest stroke(.534) and CHF(.503) 
estimates were found with the SF-6D. The lowest estimates for stroke(.189), MI(.516) 
and CHF(.189) were from the EQ-5DUK, but the lowest estimates for hyperten-
sion(.583) and diabetes(.618) were from the SF-6D. The EQ-5DUK resulted in the 
largest marginal utility decrement for all conditions. The smallest decrement for 
hypertension(−.002) and diabetes(−.022) resulted from the SF-6D, but from the 
EQ-5DUS for stroke(−.069) and CHF(−.055). When these estimates were applied to 
the model, the resulting QALYs gained from the intervention were greatest from the 
EQ-5DUS(11.32) and least from the EQ-5DUK(9.77). Incremental QALYs gained 
were greatest for EQ-5DUK(3.278) and least for the SF-6D(2.880). The ICER varied 
from $46,000–$52,000 depending on the instrument/tariff. CONCLUSIONS: Differ-
ent utility instruments/tariffs resulted in unsystematic differences in chronic condition 
utilities, but the marginal decrement in each of these conditions was systematically 
lower for the EQ-5DUK and may be a trend across all conditions. Incremental QALYs 
gained differed by instrument/tariff and the ICER varied from $46,000–$52,000.
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RELIABILITY OF HEALTH UTILITIES INDEX (HUI) SCORES: PATIENT 
AND PARENT INTER-RATER AGREEMENT ACROSS TWO CLINICAL 
TRIALS OF TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA 
(ALL) IN CHILDHOOD
Horsman JR1, Rae CS2, Furlong W1, Silverman LB3, Sallan SE3, Athale U2, Barr RD2
1Health Utilities Inc., Dundas, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 
3Harvard Medical School, Boston, MA, USA
OBJECTIVES: To assess differences in the reliability of HUI Mark 3 (HUI3) health-
related quality of life (HRQL) utility scores for patients between self and parent 
assessments across two Dana-Farber Cancer Institute (DFCI) clinical trials for treat-
ment of ALL during childhood. METHODS: Patients were enrolled in either the DFCI 
95-001 or 00-001trial, and were ≥12 years of age at the time of HUI survey. Patients 
and parents, blind to each other, completed HUI questionnaires at each of 5 trial 
phases: induction; CNS prophylaxis; intensiﬁcation; continuation; and post-treatment. 
Reliability was assessed in terms of inter-rater agreement of individual scores and 
differences in mean scores. Agreement was quantiﬁed using the single-measure 
two-way mixed model intra-class correlation coefﬁcient (ICC). An ICC of 0.41–0.60 
represents moderate reliability, 0.61–0.80 good reliability, and 0.81–1.00 very good 
reliability. Mean differences of >0.03 are clinically important. Statistical signiﬁcance 
was set at p < 0.05. RESULTS: The number of patient and parent paired assessments 
varied by assessment phase for both the 95-001 (minimum = 29, maximum = 50) and 
the 00-001 (minimum = 28, maximum = 54) trials. ICCs in the two trials ranged from 
0.49 (p < 0.05) to 0.88 (p < 0.05). There was substantial overlap of ICC 95% conﬁ-
dence bounds across the two trials at each of the ﬁve assessment phases. There was 
no signiﬁcant difference (p > 0.06) between patient-parent pairs of scores at any 
assessment phase in either trial. The difference between trials in mean patient-parent 
scores was ≤0.03 and insigniﬁcant (p > 0.08) for each of the 5 assessment phases. 
CONCLUSIONS: Agreement between patient and parent scores was moderate or 
better for all assessment phases in both trials. There were no important differences in 
mean patient and parent scores for any of the assessment phases of the two trials. 
Inter-rater reliability of scores was similar across the two trials. Parental assessments 
provide acceptable and consistent estimates of HRQL for children.
UT4
EVALUATING WILLINGNESS TO PAY THRESHOLDS FOR A DEMENTIA 
CAREGIVING INTERVENTION
Jutkowitz E, Gitlin L, Pizzi LT
Thomas Jefferson University, Philadelphia, PA, USA
OBJECTIVES:—Assess the methodological challenges of evaluating appropriate will-
ingness to pay thresholds (WTP) in cost-effectiveness studies which do not use a 
societal perspective or a QALY outcome measure. METHODS:—Tailored Activity 
Program (TAP), an intervention designed to reduce caregiver burden for dementia 
patients, served as a case study. Caregiver interventions such as TAP employ an 
individual perspective and non-QALY outcome measures such that standard societal 
WTP thresholds are not applicable. Two outcome measures related to caregiver 
burden were used 1) reduction in hours “on duty,” and 2) reduction in hours “doing 
things.” To estimate appropriate WTP values for each TAP outcome measure, we 
identiﬁed three studies which met these inclusion criteria: 1) published studies in the 
past 5 years using contingent valuation methodology to identify WTP, 2) assessed 
WTP for a dementia-related intervention that required an out-of-pocket expenditure, 
and 3) asked caregivers what they would be willing to pay for an outcome of reducing 
caregiver burden. We also assessed WTP based on the potential ﬁnancial savings 
caregivers could achieve from purchasing TAP. To assess proportion of time TAP was 
cost-effective, we built a Monte Carlo simulation to test the four WTP values identi-
ﬁed. RESULTS:—For the outcome measure “on duty” WTP varied between $1.06/
hr–$4.58/hr. WTP for the outcome measure “doing things” varied between $2.21/
hr–$9.57/hr. Applying WTP values to TAP indicates TAP cost-effectiveness varies 
between 50%-80% for both outcome measures. CONCLUSIONS:—If WTP data can 
not be collected prospectively or societal values can not be applied, evaluating WTP 
using comparable studies appears to be an acceptable method for informing decisions 
makers of potential cost-effectiveness. Application of WTP to TAP shows potential 
cost-effectiveness that can be expected under different WTP scenarios.
POSTER SESSION I
CONCEPTUAL PAPERS & RESEARCH ON METHODS – Clinical  
Outcomes Methods
PMC1
EVALUATING CLINICIAN REPORTED OUTCOME (CRO) ENDPOINTS 
FOR FDA REGULATORY APPROVALS
Nixon A, Gallop K
Oxford Outcomes Ltd, Oxford, Oxon, UK
OBJECTIVES: Clinician reported outcomes (CROs) are the most commonly observed 
endpoint in FDA approved product labels (Wilke et al, 2004) but few have been 
adequately scrutinized in terms of their suitability as endpoints. This study evaluates 
four widely used CROs in order to assess their suitability as endpoints for regulatory 
approvals. METHODS: Published evidence on the Karnofsky Performance Status 
